Moving away from the traditional “one-size-fits-all” approach to medicine, the precision medicine approach tailors treatment and prevention strategies to an individual’s unique characteristics, aiming to provide more effective and targeted healthcare interventions. Intralytix, a biotech company, is pioneering in precision approach in phage therapy.
Founded in 1998, Intralytix is dedicated to developing safe, sustainable, and highly targeted phage-based solutions for a broad range of applications. From its inception, Intralytix has been developing phage-based products targeting food safety and environmental sanitation to cutting-edge treatments, most of them FDA approved.
Choosing phages
At Intralytix, the stark difference between phages and antibiotics is explored at its best. As evidence shows, the phages are highly specific to their bacterial host, causing no harm to the surrounding healthy microbiota. Above all, the phages are replicating only at the infection site, leading to a higher concentration at the site.
Safety of the products
Operating under strict cGMP conditions, the rigorous screening processes ensure the commercial phage production with genomic integrity and host specificity. The company has many phage products manufactured targeting food, medicine, and the environment.
Intralytix Products and Applications
Intralytix, using phages, is thriving in many sectors, including food and medicine. Many of its phage products are enhancing food safety by targeting harmful bacteria in foods. In the medical field, Intralytix’s products are being explored in clinical trials, offering potential solutions to antimicrobial resistance.
The company offers many dietary supplements like PhageBiotix™ and SuperBiotix™, which work on optimizing the gut microbiome.
Intralytix has the highest number of FDA-and USDA-approved phage products for food safety, like
- ListShield, which is the first-ever FDA-approved phage product for food safety, targets Listeria monocytogenes.
- SalmoFresh™, targeting Salmonella
- ShigaShield™, targeting Shigella species and is approved for direct application to food with no labeling requirement.
- CampyShield™ targets Campylobacter spp. and can be applied directly to foods.
- EcoShield™ PX, used against Shiga-toxin-producing E. coli (STEC), including E. coli O157:H7 and other “big six” serotypes.
Phage therapy is increasingly gaining momentum and is currently being extensively researched as an additional tool for combating antibiotic-resistant infections. Also, the precision targeting mechanism and phage’s natural adaptability reduce the risk of resistance over time. However, a number of other phage properties can still be explored to make new products commercially.
For more phage-related global news updates, click here
.
